Literature DB >> 21221483

Resistance to inhibitors of the human immunodeficiency virus type 1 integration.

Daria J Hazuda1.   

Abstract

This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 infection.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21221483

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN： 1413-8670            Impact factor:   1.949


  10 in total

Review 1.  HIV integrase inhibitors: 20-year landmark and challenges.

Authors:  Mathieu Métifiot; Christophe Marchand; Yves Pommier
Journal:  Adv Pharmacol       Date:  2013

2.  HIV Drug Resistance and the Advent of Integrase Inhibitors.

Authors:  Peter K Quashie; Thibault Mesplède; Mark A Wainberg
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

3.  Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients.

Authors:  Krishan K Pandey
Journal:  Clin Med Rev Ther       Date:  2011-12-20

4.  Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors.

Authors:  Said A Hassounah; Thibault Mesplède; Peter K Quashie; Maureen Oliveira; Paul A Sandstrom; Mark A Wainberg
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

5.  Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations.

Authors:  Janani Varadarajan; Mary Jane McWilliams; Stephen H Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

6.  Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.

Authors:  Peter K Quashie; Thibault Mesplède; Ying-Shan Han; Tamar Veres; Nathan Osman; Said Hassounah; Richard D Sloan; Hong-Tao Xu; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

7.  Role of raltegravir in the management of HIV-1 infection.

Authors:  N Lance Okeke; Charles Hicks
Journal:  HIV AIDS (Auckl)       Date:  2011-07-15

Review 8.  The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance.

Authors:  Mark A Wainberg
Journal:  Scientifica (Cairo)       Date:  2012-12-31

9.  Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco.

Authors:  Najwa Alaoui; Moulay Abdelaziz El Alaoui; Nadia Touil; Hicham El Annaz; Marouane Melloul; Reda Tagajdid; Naoufal Hjira; Mohamed Boui; El Mostapha El Fahime; Saad Mrani
Journal:  BMC Res Notes       Date:  2018-06-08

10.  Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.

Authors:  Tomas Doyle; David T Dunn; Francesca Ceccherini-Silberstein; Carmen De Mendoza; Frederico Garcia; Erasmus Smit; Esther Fearnhill; Anne-Genevieve Marcelin; Javier Martinez-Picado; Rolf Kaiser; Anna Maria Geretti
Journal:  J Antimicrob Chemother       Date:  2015-08-26       Impact factor: 5.790
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.